ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
Insider transactions by Paul Elliot Mann, CEO, director and 10% owner of ASP Isotopes Inc. (ASPI). The Form 4 reports multiple transactions on September 8-9, 2025. The filing shows sales totaling 447,263 shares disposed through Rule 10b5-1 "sell to cover" and net-share settlements at weighted-average prices reported around $8.14–$8.58. The reporting person also acquired or was issued stock/derivative awards: 216,000 and 1,000,000 employee stock options (exercise price $2) reported as acquired on 09/09/2025. Following these transactions, the reporting person beneficially owned 8,084,191 shares (direct).
The filing discloses that some dispositions were effected under a 10b5-1 trading plan adopted June 9, 2025 to cover tax withholding for vesting restricted stock and that other share withholdings satisfied option exercise obligations. No additional financial results or forward-looking statements are included.
Form 144 filing for ASP Isotopes Inc. (ASPI) reports a proposed sale of 8,438 shares of common stock through Independent Trading Group (ITG) on NASDAQ with an aggregate market value of $69,191.60. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and indicates the securities were granted as equity compensation. The filing shows 91,913,109 shares outstanding for the issuer and lists the approximate sale date as 09/08/2025. No securities were reported sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 Notice: The filing discloses a proposed sale of 8,438 shares of common stock of ASP Isotopes Inc. (ASPI) with an aggregate market value of $69,191.60. The securities are to be sold through Independent Trading Group (ITG) Inc., and the sale is identified for 09/08/2025 on the NASDAQ. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and the acquisition was paid as equity compensation on the same date. The form states there were no sales by the filer in the prior three months and includes the standard signature representation regarding material nonpublic information.
ASP Isotopes Inc. reported that its Board of Directors increased its size to seven members and elected Ralph L. Hunter as a Class II director, effective September 8, 2025. His term will run until the Company’s 2027 annual meeting of stockholders or until earlier resignation or removal, and he was also named to the Board of Managers of Quantum Leap Energy LLC, a wholly owned subsidiary.
Hunter, age 60, has over 35 years of nuclear power generation experience, including leadership roles at RC Nuclear Consultants, Orion Nuclear Energy, and Constellation-related nuclear development entities, as well as service on the U.S. Civil Nuclear Trade Advisory Committee. In connection with his election, he received an award of 10,470 shares of restricted stock under the 2022 Equity Incentive Plan, vesting in full on the one-year anniversary of the grant date, and will be compensated under the Company’s non-employee director compensation policy.
Moore Duncan, a director of ASP Isotopes Inc. (ASPI), reported the sale of 75,000 shares on 08/29/2025 at a weighted average price of $9.2831. After the sale he beneficially owned 994,553 shares. The filing states the sale included shares sold to satisfy income tax liabilities arising from the vesting of a previously granted restricted stock award for 200,000 shares. The weighted-average price represents multiple trades executed between $8.95 and $10.20. The Form 4 was signed by an attorney-in-fact on 09/03/2025. This disclosure records an insider disposition tied to tax withholding for a stock award.
ASP Isotopes Inc. filed a current report to disclose that it issued a letter to shareholders dated September 2, 2025. The company is furnishing this shareholder letter as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is intended to provide broadly available information to the market. The filing specifies that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other SEC documents if specifically referenced.
ASP Isotopes Inc. (ASPI) filed a Form 144 notifying the proposed sale of 75,000 shares of its common stock through Independent Trading Group (ITG) on the NASDAQ with an aggregate market value of $789,750. The filer acquired 200,000 shares as a restricted stock award on August 16, 2023, paid by equity compensation on that date. The approximate date of sale is listed as August 29, 2025. The filing reports no securities sold during the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
ASP Isotopes Inc. reports it will host a corporate access event for South African investors ahead of an anticipated secondary listing of its common stock on the Johannesburg Stock Exchange, with trading on the JSE Main Board expected to begin on August 27, 2025, while retaining its primary Nasdaq listing and not raising new capital in connection with the listing. The company provides operational updates across several isotope programs in Pretoria, including commercial production of Silicon-28, where first enriched samples were shipped to a U.S. customer in August 2025, and Ytterbium-176, where enrichment has reached up to 92.4% and the first fully enriched batch is expected by the end of August 2025 with shipments to follow.
The Ytterbium-176 plant is running in batch mode and has had a 3–4 week delay in equipment for semi-continuous processing, shifting that transition to late third or early fourth quarter 2025 from prior late August guidance. The company has obtained initial permits to import controlled laser equipment for Nickel-64, Gadolinium-160 and Zinc-68 and is accelerating enrichment facility plans. Its Carbon plant, originally prepared for Carbon-14, is now enriching Carbon-12 to 99.99% for a U.S. customer, with first commercial product now expected in September 2025 after a regulatory-related delay, and demand for Carbon-12 is described as significantly higher than for Carbon-14.
ASP Isotopes reiterates expectations to initiate a spin-out of its Quantum Leap Enrichment subsidiary as a standalone public company during the second half of 2025 and continues to anticipate closing the Renergen acquisition in the third quarter of 2025, in each case subject to required approvals and consents. Company, QLE and Renergen representatives also plan to participate in a RedChip conference call on August 28, 2025.
ASP Isotopes Inc. reported that it and its subsidiary, Quantum Leap Energy LLC, entered into a Memorandum of Understanding with Fermi America for a U.S. joint venture. The parties intend to collaborate on the research, development and construction of an advanced nuclear fuel research and production facility at the planned 11GW HyperGrid Campus in Carson County, Texas.
The company disclosed this arrangement through a press release dated August 15, 2025, which is attached as an exhibit and incorporated by reference, except for three specified paragraphs.
AWM Investment Company, Inc. reports beneficial ownership of 3,931,186 shares of ASP Isotopes Inc., representing 4.3% of the outstanding common stock. AWM states it is the investment adviser to five funds and holds sole voting and sole dispositive power over the shares allocated across those funds, with individual fund holdings disclosed in the filing. The disclosure identifies the funds by name and provides a per‑fund share breakdown, making the ownership position transparent.
Filing statements indicate the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing also names the controlling principals associated with the funds and confirms there is no shared voting or dispositive power reported.